Post Reply
10281-10300 of 10564
Malaysia gloves is the king
Not here
But good to see if going up
Stagnant for a Long time
Not here
But good to see if going up
Stagnant for a Long time
Both Riverstone and UG have lower PE as compared to sector avg in Malaysia.
This may be due to lack of investor awareness and interests before the Pandemic..
Imo, they should be revalued closer to their Malaysia peers, say about 22x to 25x as compare to 35x overvthe causeway. Otherwise, they are good targets for takeover by the Malaysian companies. Just a thot.
98mich98 ( Date: 11-May-2020 22:38) Posted:
|
good eye.
98mich98 ( Date: 11-May-2020 22:32) Posted:
|
Base on 17x PE price shb be $2.10
Base on PE 22x price shb be $2.70
Other top 3 companies are in tge average of PE 35x 😀
17x havnt factor in the 1.4b production lines which will show in 4th Q.
So FY revenue will increase by 15% which will reduce the PE
Yes, Riverstone' s PE is around 17X currently, feels about right valuation based on historical of around 15~20X.
potential to go $1.7 but not overnight, of course!
potential to go $1.7 but not overnight, of course!
gregtan123 ( Date: 11-May-2020 20:50) Posted:
|
Anyone finds it strange Medtec' s latest Q result is showing NP% of 9.22% instead of its historical NP% of 1.5%~1.77%?
did they fully automate processes in just one Qtr, eliminating all opex? Something is definitely missing in the disclosure.
(if using its historical NP%, its EPS is actually going to be around 0.004 and PE ratio 57X).
take extra care
did they fully automate processes in just one Qtr, eliminating all opex? Something is definitely missing in the disclosure.
(if using its historical NP%, its EPS is actually going to be around 0.004 and PE ratio 57X).
take extra care
Not just fantastic profits, order ramps up as well.
easywin ( Date: 11-May-2020 21:43) Posted:
|
Outlook
Due to the surge in worldwide demand for products such examination gloves and facemasks, the Group has been witnessing an uptick in orders from both new and existing customers during this period. Accordingly, the Group is working closely with its customers to meet their needs and fulfill orders, especially for examination gloves which are urgently required in healthcare systems worldwide. Moving into the remainder of FY2020, phase 6 of the Group&rsquo s expansion plans is on track to lift capacity progressively by up to 1.4 billion to a total of 10.4 billion pieces of gloves per annum by the fourth quarter ended 31 December 2020 (&ldquo 4Q2020&rdquo ), further helping the Group to alleviate pressure on supply.
The health and safety of all employees are of utmost importance and priority for the Group. Accordingly, the Group has implemented stringent safety measures across all of its facilities, while complying with health advisories issued by governments in Malaysia and across the region where the Group operates. As developments surrounding Covid-19 remain fluid and continues to evolve, the Group will monitor the situation closely and keep shareholders updated on material developments, if any, via SGXNet.
Executive Chairman and CEO, Mr. Wong Teek Son ( ) remarked, &ldquo Due to the surge in healthcare glove orders resulting from the Covid-19 pandemic, we have been ramping up production and reducing downtime for our production lines to meet this robust demand. Completion of our new facility for phase 6 of our capacity expansion plans has come at an opportune time, and we are progressively commissioning new lines to satisfy our customers&rsquo urgent need for examination gloves. By 4Q2020, we expect to raise capacity by up to 1.4 billion pieces to a total of 10.4 billion pieces of gloves per annum to help alleviate this supply crunch. During this difficult period, we understand that it is our collective duty and responsibility to ensure that the supply of these essential healthcare supplies are met, as we work together with healthcare systems and practitioners around the world to combat the virus.&rdquo
&ndash The End &ndash
Due to the surge in worldwide demand for products such examination gloves and facemasks, the Group has been witnessing an uptick in orders from both new and existing customers during this period. Accordingly, the Group is working closely with its customers to meet their needs and fulfill orders, especially for examination gloves which are urgently required in healthcare systems worldwide. Moving into the remainder of FY2020, phase 6 of the Group&rsquo s expansion plans is on track to lift capacity progressively by up to 1.4 billion to a total of 10.4 billion pieces of gloves per annum by the fourth quarter ended 31 December 2020 (&ldquo 4Q2020&rdquo ), further helping the Group to alleviate pressure on supply.
The health and safety of all employees are of utmost importance and priority for the Group. Accordingly, the Group has implemented stringent safety measures across all of its facilities, while complying with health advisories issued by governments in Malaysia and across the region where the Group operates. As developments surrounding Covid-19 remain fluid and continues to evolve, the Group will monitor the situation closely and keep shareholders updated on material developments, if any, via SGXNet.
Executive Chairman and CEO, Mr. Wong Teek Son ( ) remarked, &ldquo Due to the surge in healthcare glove orders resulting from the Covid-19 pandemic, we have been ramping up production and reducing downtime for our production lines to meet this robust demand. Completion of our new facility for phase 6 of our capacity expansion plans has come at an opportune time, and we are progressively commissioning new lines to satisfy our customers&rsquo urgent need for examination gloves. By 4Q2020, we expect to raise capacity by up to 1.4 billion pieces to a total of 10.4 billion pieces of gloves per annum to help alleviate this supply crunch. During this difficult period, we understand that it is our collective duty and responsibility to ensure that the supply of these essential healthcare supplies are met, as we work together with healthcare systems and practitioners around the world to combat the virus.&rdquo
&ndash The End &ndash
i hope go back 1.30 hehe
Riverstone and medtec customers are a bit different.
Riverstone dont just make ordinary Mask and gloves.
And they serve healthcare and semi tech.
The 17x PE at $1.47 is still much lower compare to topglove
We shall see $1.60 tomorrow?
mr greg tan trying to lure ppl buy medtec! xD
gregtan123 ( Date: 11-May-2020 20:50) Posted:
|
authority should check Riverstone.....no news suddenly up so much before announcement.
insider trading.
[Perspective: which is Value/Undervalued?]
Riverstone Net Profit in SGD: 15,265,129.58 or 15 Million x 4 (note they report in Ringgit)
Medtecs Net Profit in SGDL 5,202,709.92 or 5 Million x 4 (note they report in USD)
Riverstone EPS: 0.08239352 SGD
Medtecs EPS: 0.03787845 SGD
Riverstone PE at current price of 1.47 is 17.8412089
Medtecs PE at current price of 0.178 is 4.699241912
17x PE versus 4.7x PE. Which better buy LT?
Riverstone Net Profit in SGD: 15,265,129.58 or 15 Million x 4 (note they report in Ringgit)
Medtecs Net Profit in SGDL 5,202,709.92 or 5 Million x 4 (note they report in USD)
Riverstone EPS: 0.08239352 SGD
Medtecs EPS: 0.03787845 SGD
Riverstone PE at current price of 1.47 is 17.8412089
Medtecs PE at current price of 0.178 is 4.699241912
17x PE versus 4.7x PE. Which better buy LT?
furnaces ( Date: 11-May-2020 20:21) Posted:
|
Wow, 50% increase in net profit.
prob gonna leave this in till 2 dollar
http://riverstone.listedcompany.com/news.html/id/776476
News out
50% increase in net profit
another AEM
More to come